Celleron targets Daiichi Sankyo with Roche’s unwanted rare cancer drugUK biotech Celleron Therapeutics has bought a licence to develop, manufacture and market emactuzumab, an unwanted drug from Share XCelleron targets Daiichi Sankyo with Roche’s unwanted rare cancer drughttps://pharmaphorum.com/news/celleron-targets-daiichi-sankyo-with-roches-unwanted-rare-cancer-drug/
